{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:14:22Z","timestamp":1787314462389,"version":"build-2736575974"},"reference-count":27,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2023YC27"],"award-info":[{"award-number":["2023YC27"]}]},{"name":"Beijing Natural Science funding","award":["L254077"],"award-info":[{"award-number":["L254077"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2025YC-GD01"],"award-info":[{"award-number":["2025YC-GD01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Background &amp; Aims: This study aimed to evaluate the feasibility of vonoprazan\u2013minocycline (VM) dual therapy for Helicobacter pylori infection. Methods: In this open-label RCT, 120 H. pylori-infected patients (60 treatment-na\u00efve and 60 treatment-failure cases) were randomized to receive vonoprazan\u2013amoxicillin dual therapy (VA: vonoprazan 20 mg b.i.d. + amoxicillin 1.0 g t.i.d., control group) or VM dual therapy (vonoprazan 20 mg b.i.d. + minocycline 100 mg b.i.d., test group) for 14 days. The primary outcome was eradication rates. Secondary outcomes included adverse effects (AEs). Results: As first-line treatment, eradication rates were 96.7% (VA) vs. 90.0% (VM) in intention-to-treat (ITT) analysis (p = 0.30) and 96.7% (VA) vs. 96.4% (VM) in per-protocol (PP) analysis (p = 0.96). For rescue treatment, eradication rates were 86.7% (VA) vs. 76.7% (VM) in ITT (p = 0.32) and 89.7% (VA) vs. 79.3% (VM) in PP (p = 0.28). Overall eradication rates were 91.7% (VA) vs. 83.3% (VM) in ITT (p = 0.17) and 93.2% (VA) vs. 87.7% (VM) in PP (p = 0.31). VM had a higher incidence of AEs than VA (30.0% vs. 10.0%, p = 0.006), with dizziness being the most common (18.3%). Conclusions: VM dual therapy was shown to be an effective and safe treatment option, demonstrating comparable eradication rates to VA dual therapy. While VM had a slightly higher incidence of AEs, they were generally mild and manageable. VM remained a valuable alternative for patients with penicillin allergies or amoxicillin resistance.<\/jats:p>","DOI":"10.3390\/pathogens14111121","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:15:14Z","timestamp":1762175714000},"page":"1121","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Exploratory Study on Efficacy and Safety of Minocycline-Based Dual Therapy for Helicobacter pylori Eradication"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3549-6846","authenticated-orcid":false,"given":"Wen","family":"Gao","sequence":"first","affiliation":[{"name":"GI Department, Peking University First Hospital, Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2675-2677","authenticated-orcid":false,"given":"Jingwen","family":"Li","sequence":"additional","affiliation":[{"name":"School of Medicine, Tsinghua University, Beijing 100084, China"},{"name":"F. Widjaja Inflammatory Bowel Disease Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Tian","sequence":"additional","affiliation":[{"name":"GI Department, Peking University First Hospital, Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyi","family":"Ge","sequence":"additional","affiliation":[{"name":"GI Department, Peking University First Hospital, Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Wang","sequence":"additional","affiliation":[{"name":"GI Department, Peking University First Hospital, Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiang","family":"Liu","sequence":"additional","affiliation":[{"name":"GI Department, Peking University First Hospital, Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Li","sequence":"additional","affiliation":[{"name":"GI Department, Peking University First Hospital, Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6434-1101","authenticated-orcid":false,"given":"Hong","family":"Cheng","sequence":"additional","affiliation":[{"name":"GI Department, Peking University First Hospital, Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: The Maastricht VI\/Florence consensus report","volume":"71","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1053\/j.gastro.2024.06.038","article-title":"AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice: Expert Review","volume":"167","author":"Patel","year":"2024","journal-title":"Gastroenterology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"787","DOI":"10.14309\/ajg.0000000000003084","article-title":"Comparative efficacy and safety of Potassium-Competitive Acid Blocker (P-CAB) based dual, triple and quadruple regimens for first line H. pylori infection treatment: A systematic review and network meta-analysis","volume":"120","author":"Rokkas","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(23)00281-9","article-title":"Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: An updated systematic review and meta-analysis","volume":"9","author":"Hong","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/gutjnl-2024-332640","article-title":"Simplified Helicobacter pylori therapy for patients with penicillin allergy: A randomised controlled trial of vonoprazan-tetracycline dual therapy","volume":"73","author":"Gao","year":"2024","journal-title":"Gut"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.3748\/wjg.v30.i17.2354","article-title":"Minocycline in the eradication of Helicobacter pylori infection: A systematic review and meta-analysis. World J Gastroenterol","volume":"30","author":"Zhou","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/CM9.0000000000002629","article-title":"Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial","volume":"136","author":"Suo","year":"2023","journal-title":"Chin. Med. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00535-023-01991-y","article-title":"Minocycline vs. tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: A multicentre, randomized controlled trial","volume":"58","author":"Huang","year":"2023","journal-title":"J. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e13138","DOI":"10.1111\/hel.13138","article-title":"Optimization of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Real-World Evidence Study","volume":"29","author":"Huang","year":"2024","journal-title":"Helicobacter"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"i18","DOI":"10.1136\/gut.45.2008.i18","article-title":"The 13C urea breath test in the diagnosis of Helicobacter pylori infection","volume":"45","author":"Savarino","year":"1999","journal-title":"Gut"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa1909666","article-title":"Family History of Gastric Cancer and Helicobacter pylori Treatment","volume":"382","author":"Choi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e12947","DOI":"10.1111\/hel.12947","article-title":"A real-world exploratory study on the feasibility of vonoprazan and tetracycline dual therapy for the treatment of Helicobacter pylori infection in special populations with penicillin allergy or failed in previous amoxicillin-containing therapies","volume":"28","author":"Gao","year":"2023","journal-title":"Helicobacter"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1515\/hsz-2013-0292","article-title":"Tetracycline antibiotics and resistance mechanisms","volume":"395","author":"Nguyen","year":"2014","journal-title":"Biol. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.clinthera.2005.09.005","article-title":"Safety of doxycycline and minocycline: A systematic review","volume":"27","author":"Smith","year":"2005","journal-title":"Clin. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e12839","DOI":"10.1111\/hel.12839","article-title":"Doxycycline and minocycline in Helicobacter pylori treatment: A systematic review and meta-analysis","volume":"26","author":"Zhao","year":"2021","journal-title":"Helicobacter"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"You, S., Tang, X., Zhou, J., Shen, Y., Song, X., Benghezal, M., Marshall, B.J., Tang, H., and Li, H. (2024). Minocycline\/Amoxicillin-Based Bismuth Quadruple Therapy for Helicobacter pylori Eradication: A Pilot Study. Microorganisms, 12.","DOI":"10.3390\/microorganisms12030429"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e13022","DOI":"10.1111\/hel.13022","article-title":"Efficacy and safety of minocycline quadruple therapy for Helicobacter pylori eradication: A meta-analysis of RCTs","volume":"28","author":"Gao","year":"2023","journal-title":"Helicobacter"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/hel.12313","article-title":"Rabeprazole, Minocycline, Amoxicillin, and Bismuth as First-Line and Second-Line Regimens for Helicobacter pylori Eradication","volume":"21","author":"Song","year":"2016","journal-title":"Helicobacter"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40265-023-01991-5","article-title":"Vonoprazan: A Review in Helicobacter pylori Infection","volume":"84","author":"Shirley","year":"2024","journal-title":"Drugs"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1128\/AAC.11.4.712","article-title":"Side effects of minocycline: A double-blind study","volume":"11","author":"Fanning","year":"1977","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1128\/AAC.12.5.642","article-title":"Side effects of minocycline: Different dosage regimens","volume":"12","author":"Gump","year":"1977","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/00365528909091311","article-title":"Does omeprazole improve antimicrobial therapy directed towards gastric Campylobacter pylori in patients with antral gastritis? A pilot study","volume":"24","author":"Unge","year":"1989","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"799","DOI":"10.5009\/gnl20242","article-title":"Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of Helicobacter pylori Eradication?","volume":"15","author":"Sue","year":"2021","journal-title":"Gut Liver"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2036.1994.tb00285.x","article-title":"Short report: Omeprazole-tetracycline combinations are inadequate as therapy for Helicobacter pylori infection","volume":"8","author":"Genta","year":"1994","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e13094","DOI":"10.1111\/hel.13094","article-title":"Vonoprazan-based therapies versus PPI-based therapies in patients with H. pylori infection: Systematic review and meta-analyses of randomized controlled trials","volume":"29","author":"Liu","year":"2024","journal-title":"Helicobacter"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2022.05.055","article-title":"Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial","volume":"163","author":"Chey","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s10620-023-07886-5","article-title":"Why the Vonoprazan Helicobacter pylori Therapies in the US-European Trial Produced Unacceptable Cure Rates","volume":"68","author":"Graham","year":"2023","journal-title":"Dig. Dis. Sci."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/14\/11\/1121\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T14:08:57Z","timestamp":1762178937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/14\/11\/1121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["pathogens14111121"],"URL":"https:\/\/doi.org\/10.3390\/pathogens14111121","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]}}}